Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Motivation: Transcriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery. Nevertheless, key limitations of the current drug connectivity-mapping paradigm have been long overlooked, including the lack of effective means to determine optimal query gene signatures. Results: The novel approach Dr Insight implements a frame-breaking statistical model for the ‘hand-shake’ between disease and drug data. The genome-wide screening of concordantly expressed genes (CEGs) eliminates the need for subjective selection of query signatures, added to eliciting better proxy for potential disease-specific drug targets. Extensive comparisons on simulated and real cancer datasets have validated the superior performance of Dr Insight over several popular drug-repurposing methods to detect known cancer drugs and drug–target interactions. A proof-of-concept trial using the TCGA breast cancer dataset demonstrates the application of Dr Insight for a comprehensive analysis, from redirection of drug therapies, to a systematic construction of disease-specific drug-target networks. Availability and implementation: Dr Insight R package is available at https://cran.r-project.org/web/packages/DrInsight/index.html. Supplementary information: Supplementary data are available at Bioinformatics online.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASGARD on each cluster is related to DrInsight, a concordantly expressed genes (CEG) based, enhanced drug repurposing method compared to other signature-based searching methods30.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206 · cited 1×
“Finally, in combination with several external gene set databases such as Gene Ontology (GO) (Ashburner et al., 2000), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000) and NCI Pathway Interaction Database (PID) (Schaefer et al., 2009), the drug–CEG interactions serve as the…”
MethodKEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232 · cited 2×
“Finally, in combination with several external gene set databases such as Gene Ontology (GO) (Ashburner et al., 2000), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000) and NCI Pathway Interaction Database (PID) (Schaefer et al., 2009), the drug–CEG interactions serve as the skeleton to assemble…”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citationPID: the Pathway Interaction Database
Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., & Buetow, K. H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn653 · Cited by 1,603
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
Pathway Commons, a web resource for biological pathway data
Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1039 · Cited by 1,101
STITCH: interaction networks of chemicals and proteins
Kuhn, M., von Mering, C., Campillos, M., Jensen, L. J., & Bork, P. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm795 · Cited by 998
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816 · cited 1×
“We first generated the prototype list (PRL) of each individual drug by merging all of its instances in CMap into one ranked gene list [12].”
MethodVarambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.001 · Cited by 800 · cited 1×
“The microarray-based prostate cancer (GSE3325) gene expression dataset [2], SLE gene expression dataset (GSE65391) and HBV dataset (GSE69590) were obtained from the Gene Expression Omnibus (GEO) database.”
MethodSirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 799
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Banchereau, R., Hong, S., Cantarel, B., Baldwin, N., Baisch, J., Edens, M., Cepika, A.-M., Acs, P., Turner, J., Anguiano, E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.008 · Cited by 731
Self-citationTreatment of Obesity with Celastrol
Liu, J., Lee, J., Salazar Hernandez, M. A., Mazitschek, R., & Ozcan, U. (2015) · Cell · doi:10.1016/j.cell.2015.05.011 · Cited by 726 · cited 1×
“The size range was determined based on numerous existing CMap applications, where small (40, 100 or 150 probes [6-8]), medium (230 or 406 probes [9, 10]), and larger sizes (870 to 1000 probes [10, 11]) were used.”
MethodVigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
Davis, A. P., Murphy, C. G., Saraceni-Richards, C. A., Rosenstein, M. C., Wiegers, T. C., & Mattingly, C. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn580 · Cited by 324
A review of connectivity map and computational approaches in pharmacogenomics
Musa, A., Ghoraie, L. S., Zhang, S.-D., Galzko, G., Yli-Harja, O., Dehmer, M., Haibe-Kains, B., & Emmert-Streib, F. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbw112 · Cited by 260
Transcriptional data: a new gateway to drug repositioning?
Iorio, F., Rittman, T., Ge, H., Menden, M., & Saez-Rodriguez, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.014 · Cited by 237
Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice
Lee, J., Liu, J., Feng, X., Salazar Hernández, M. A., Mucka, P., Ibi, D., Choi, J. W., & Ozcan, U. (2016) · Nature Medicine · doi:10.1038/nm.4145 · Cited by 210
Outlier sums for differential gene expression analysis
Tibshirani, R., & Hastie, T. (2007) · Biostatistics · doi:10.1093/biostatistics/kxl005 · Cited by 174 · cited 1×
“The CEGs are further pooled together to calculate an overall connectivity score for each individual drug based on an outlier-sum method (Gu et al., 2012; Tibshirani and Hastie, 2007) to test drug treatment effect (Fig.”
MethodZhao, W., Prijic, S., Urban, B. C., Tisza, M. J., Zuo, Y., Li, L., Tan, Z., Chen, X., Mani, S. A., & Chang, J. T. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1970 · Cited by 172
Terazosin activates Pgk1 and Hsp90 to promote stress resistance
Chen, X., Zhao, C., Li, X., Wang, T., Li, Y., Cao, C., Ding, Y., Dong, M., Finci, L., Wang, J.-H., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1657 · Cited by 156 · cited 1×
“The size range was determined based on numerous existing CMap applications, where small (40, 100 or 150 probes [6-8]), medium (230 or 406 probes [9, 10]), and larger sizes (870 to 1000 probes [10, 11]) were used.”
MethodA review of connectivity map and computational approaches in pharmacogenomics
Musa, A., Ghoraie, L. S., Zhang, S.-D., Glazko, G., Yli-Harja, O., Dehmer, M., Haibe-Kains, B., & Emmert-Streib, F. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx023 · Cited by 149 · cited 1×
“4 CEGs significantly improve drug target prediction and Figure 4) that CEGs are better proxy for drug target prediction, compared to DEGs used by other signature-based methods [13-16].”
ResultA novel computational approach for drug repurposing using systems biology
Peyvandipour, A., Saberian, N., Shafi, A., Donato, M., & Drăghici, S. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty133 · Cited by 125
p53-dependent repression of polo-like kinase-1 (PLK1)
McKenzie, L., King, S., Marcar, L., Nicol, S., Dias, S. S., Schumm, K., Robertson, P., Bourdon, J.-C., Perkins, N., Fuller-Pace, F., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13532 · Cited by 117
Hunt, K. K., Deng, J., Liu, T. J., Wilson-Heiner, M., Swisher, S. G., Clayman, G. L., & Hung, M. (1997) · PubMed · Cited by 117
Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent
Xiang, M., Kim, H., Ho, V. T., Walker, S. R., Bar-Natan, M., Anahtar, M., Liu, S., Toniolo, P. A., Kroll, Y., Jones, N., et al. (2016) · Blood · doi:10.1182/blood-2015-07-660506 · Cited by 109 · cited 1×
“…et al., 2016b; Liu et al., 2015a), neurodegenerative diseases (Sandor et al., 2017; Siavelis et al., 2016), gastrointestinal and liver diseases (Hicks et al., 2017), stroke and sepsis (Chen et al., 2015b) and cancers (Hsieh et al., 2016; Liu et al., 2015b; Xiang et al., 2016; Zhao et al., 2016).”
BackgroundDrug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures
Lee, H., Kang, S., & Kim, W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150460 · Cited by 90
Bioinformatics methods in drug repurposing for Alzheimer’s disease
Siavelis, J. C., Bourdakou, M. M., Athanasiadis, E. I., Spyrou, G. M., & Nikita, K. S. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv048 · Cited by 87
Zhang, S.-D., & Gant, T. W. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-236 · Cited by 81 · cited 1×
“, 2006), sscMap (Zhang and Gant, 2009), NFFinder (Setoain et al.”
Setoain, J., Franch, M., Martínez, M., Tabas-Madrid, D., Sorzano, C. O. S., Bakker, A., Gonzalez-Couto, E., Elvira, J., & Pascual-Montano, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv445 · Cited by 76 · cited 1×
“NFFinder [23] Y Y N N Cogena [24] Y Y N Y Wen, et al.”
BackgroundJia, Z., Liu, Y., Guan, N., Bo, X., Luo, Z., & Barnes, M. R. (2016) · BMC Genomics · doi:10.1186/s12864-016-2737-8 · Cited by 74
Sandor, C., Robertson, P., Lang, C., Heger, A., Booth, H., Vowles, J., Witty, L., Bowden, R., Hu, M., Cowley, S. A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddw412 · Cited by 74
CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules
Lee, J. H., Kim, D. G., Bae, T., Rho, K., Kim, J. T., Lee, J.-J., Jang, Y., Kim, B. C., Park, K. M., & Kim, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042573 · Cited by 73
Pignatelli, M., Sánchez-Rodríguez, J., Santos, Á., & Perez-Castillo, A. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh308 · Cited by 72
Shigemizu, D., Hu, Z., Hung, J., Huang, C. L., Wang, Y., & DeLisi, C. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002347 · Cited by 70
MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells
Liu, Y., He, G., Wang, Y., Guan, X., Pang, X., & Zhang, B. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.05.643 · Cited by 65
Chen, H.-R., Sherr, D. H., Hu, Z., & DeLisi, C. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0212-7 · Cited by 64
Hepatitis B Virus and DNA Stimulation Trigger a Rapid Innate Immune Response through NF-κB
Yoneda, M., Hyun, J., Jakubski, S., Saito, S., Nakajima, A., Schiff, E. R., & Thomas, E. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502677 · Cited by 53 · cited 1×
“Comparable results were observed on two non-cancer datasets: systemic lupus erythematosus data (Banchereau et al., 2016) and Hepatitis B virus infection data (Yoneda et al., 2016) (Supplementary Fig.”
ResultHsieh, Y.-Y., Chou, C.-J., Lo, H.-L., & Yang, P.-M. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.27 · Cited by 49
Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy
El-Hachem, N., Gendoo, D. M. A., Ghoraie, L. S., Safikhani, Z., Smirnov, P., Chung, C., Deng, K., Fang, A., Birkwood, E., Ho, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0096 · Cited by 41
Hicks, D. F., Goossens, N., Blas-García, A., Tsuchida, T., Wooden, B., Wallace, M. C., Nieto, N., Lade, A., Redhead, B., Cederbaum, A. I., et al. (2017) · Scientific Reports · doi:10.1038/srep42563 · Cited by 40
Park, H.-Y., Im, J. Y., Kim, J., Choi, W. S., & Kim, H. K. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.21.3.325 · Cited by 35
Hameed, P. N., Verspoor, K. M., Kusljic, S., & Halgamuge, S. K. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2123-4 · Cited by 35
Liu, J., & Li, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.182 · Cited by 25 · cited 1×
“More interestingly, the HDAC inhibitor trichostatin A (TSA) was found to have antitumor activity against breast cancer not only in cell lines but also in animal models (Liu and Li, 2015; Vigushin et al., 2001).”
BackgroundExpression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma
Liu, X., Yang, X., Chen, X., Zhang, Y., Pan, X., Wang, G., & Ye, Y. (2015) · Journal of Cancer · doi:10.7150/jca.12191 · Cited by 14
Kim (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000062 · Cited by 14
Wen, Q., Kim, C.-S., Hamilton, P. W., & Zhang, S. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1066-x · Cited by 13
Systematic Analysis of the Associations between Adverse Drug Reactions and Pathways
Chen, X., Wang, Y., Wang, P., Lian, B., Li, C., Wang, J., Li, X., & Jiang, W. (2015) · BioMed Research International · doi:10.1155/2015/670949 · Cited by 11
Gu, J., Xuan, J., Riggins, R. B., Chen, L., Wang, Y., & Clarke, R. C. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts296 · Cited by 9
Self-citationEffects of 15‐Deoxy‐Δ12,14‐prostaglandin J2 on the Expression of p53 in MCF‐7 Cells
Kim, D., Kim, E., Na, H., & Surh, Y. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04913.x · Cited by 8 · cited 1×
“For instance, 15-delta prostaglandin J2, a member of cyclopentenone prostaglandins, was previously reported to induce apoptosis and cell death of breast cancer cells (Kim et al., 2009; Pignatelli et al., 2004).”
Background
Cited by
Low, Z. Y., Farouk, I. A., & Lal, S. K. (2020) · Viruses · doi:10.3390/v12091058 · Cited by 180
“0001 and an absolute fold change of ≥4 [20].”
BackgroundYang, C. G., Zhang, H., Chen, M., Wang, S., Qian, R., Zhang, L., Huang, X., Wang, J., Liu, Z., Qin, W., et al. (2022) · eLife · doi:10.7554/elife.71880 · Cited by 180
“By contrast, relatively limited efforts have been made to standardize the generation of query signatures ( Chan et al., 2019 ; Wen et al., 2016 ; Wen et al., 2015 ).”
Drug repurposing for COVID-19: Approaches, challenges and promising candidates
Ng, Y. L., Salim, C. K., & Chu, J. J. H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107930 · Cited by 159
Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa003 · Cited by 131
Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes
DeMeo, B., Nesbitt, C., Miller, S. A., Burkhardt, D. B., Lipchina, I., Fu, D., Holderrieth, P., Kim, D., Kolchenko, S., Szałata, A., et al. (2025) · Science · doi:10.1126/science.adi8577 · Cited by 86
“The comparison models included two classical baseline methods: a k - nearest Hits Non-hits”
Metadata
- Authors
- Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J.
- Affiliations
- Baylor University (US)
- Baylor Scott & White Research Institute (US)
- Stephen F. Austin State University (US)
- Corresponding author
- Gu, Jinghua
- Venue
- Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-08
- Volume
- 35
- Issue
- 16
- Pages
- 2818-2826
- ISSN
- 1367-4803 (ISSN-L)
- 1367-4811
- PMC
- PMC6691331
- OpenAlex
- W2910665348
- Cited by
- 50
- References
- 57
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 12 · 2021: 7 · 2020: 13 · 2019: 3
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Bioinformatics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Index of Texas Archaeology Open Access Grey Literature from the Lone Star State (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI082715)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- computational drug repurposing, drug-target interactions, cancer drug targets, breast cancer
- MeSH terms
- Software, Models, Statistical, Drug Discovery, Drug Repositioning, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.